Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deals Of The Week Looks At Pricing Conundrums

Dec 09 2013

• By Michael Goodman, Jessica Merrill, Wendy Diller, and Sten Stovall

Related Content

Forest’s <em>Fetzima</em> Will Test Enantiomer Exclusivity Policy Change

Aug 05 2013

Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions

Aug 21 2012

UniQure’s Glybera Is First Gene Therapy Okayed In Western Europe

Nov 02 2012

Janssen Biotech Signs Option Agreement With Molecular Partners On Use Of DARPins In Immunological Diseases

Dec 08 2011

electroCore Aims Noninvasive Neurostimulation At The Masses

Sep 12 2013

uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

Jul 10 2013

Related Companies

uniQure N.V.

uniQure N.V.

Chiesi Farmaceutici S.p.A.

Biogen, Inc.

ElectroCore, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

OncoMed Pharmaceuticals, Inc.

Forest Laboratories, Inc.

The Medicines Company

Alnylam Pharmaceuticals Inc.

Roche Holding AG

Molecular Partners AG

Allergan plc

Johnson & Johnson

Theraclone Sciences, Inc.

PharmAthene, Inc.

Nippon Zenyaku Kogyo Co Ltd

Pfizer Inc.

Additional Topics

Pricing Strategies Deals BioPharmaceutical Medical Device

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window